MIMEDX Group, Inc.

MIMEDX is a company focused on healing, providing products for wound care, burn, and surgical sectors of healthcare. With nearly two decades of experience, MIMEDX offers a portfolio of products to help clinicians manage chronic and other hard-to-heal wounds. Historically, the company focused solely on placental biologics. In 2024, MIMEDX expanded its portfolio to include animal-derived products, or xenografts. In 2025 and early 2026, the company entered into agreements with manufacturers of other wound care modalities to further broaden its product offering. MIMEDX's product portfolio is used to treat patients with chronic and hard-to-heal wounds, often when patients are not responding to conventional treatments. The company's placental allografts are human tissues derived from a donor and processed into products for multiple recipients. The manufacturing of these human-derived products starts with donated birth tissue, specifically the human placental membrane, umbilical cord, and placental disc, sourced through a donor network developed over more than a decade with hospitals and clinician groups.